NightHawk Biosciences, Inc.
(NYSE Amex Equities : HTBX)

( )
HTBX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. 0.72%52.850.9%$1374.69m
JNJJohnson & Johnson 1.40%179.460.7%$1371.52m
BMYBristol-Myers Squibb Co. 0.63%76.671.0%$1204.82m
MRKMerck & Co., Inc. 0.45%93.980.7%$1144.89m
ABBVAbbVie, Inc. -1.98%148.021.9%$1115.58m
LLYEli Lilly & Co. 1.25%302.571.1%$903.32m
AZNAstraZeneca Plc 0.30%66.411.0%$519.21m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.66%142.970.0%$461.53m
VERUVeru, Inc. 5.53%14.120.0%$336.28m
NVSNovartis AG 1.45%90.720.2%$254.85m
GSKGlaxoSmithKline Plc 0.53%44.760.2%$244.47m
HZNPHorizon Therapeutics Plc -3.29%87.385.4%$193.81m
NVONovo Nordisk A/S 0.07%107.830.1%$190.87m
SGENSeagen Inc. -0.22%139.345.7%$181.36m
VTRSViatris, Inc. -1.44%11.630.0%$163.74m

Company Profile

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.